Washington, DC 20006-5349
HELPLINE
Today, the Meso Foundation wrote a letter to the acting administrator of the EPA urging the agency to account for legacy asbestos when evaluating asbestos risk and the magnitude of the asbestos problem. This letter came as a response to the EPA’s decision to exclude legacy uses of asbestos in its problem formulation. This issue is separate from the recently publicized ‘significant new use rule.’ You can read more here.
EPA_Legacy_Comment_MesoFoundation
This episode of MesoTV features Jacob Strand, MD in an interview with Mesothelioma Applied Research Foundation’s nurse, Julie White, RN, BSN, OCN. The topic of
The U.S. Environmental Protection Agency (EPA) announced today that the first rule to be finalized under the Toxic Substance Control Act is a ban on
Data from a positive phase 2/3 clinical trial evaluating the effectiveness of a drug for mesothelioma was just published in the Journal of the American
Get the latest information about mesothelioma, clinical trials, patient stories, community events, and much more!
